-
Je něco špatně v tomto záznamu ?
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
MA. Dimopoulos, PM. Voorhees, F. Schjesvold, YC. Cohen, V. Hungria, I. Sandhu, J. Lindsay, RI. Baker, K. Suzuki, H. Kosugi, MD. Levin, M. Beksac, K. Stockerl-Goldstein, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, AK. Mylin, S....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, klinické zkoušky, fáze III, multicentrická studie, srovnávací studie
NLK
ProQuest Central
od 1980-01-03 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1980-01-03 do Před 3 měsíci
Family Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Psychology Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health Management Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Public Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
PubMed
39652675
DOI
10.1056/nejmoa2409029
Knihovny.cz E-zdroje
- MeSH
- doba přežití bez progrese choroby MeSH
- dospělí MeSH
- doutnající mnohočetný myelom * diagnóza mortalita terapie MeSH
- injekce subkutánní MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom * diagnóza epidemiologie prevence a kontrola MeSH
- monoklonální protilátky * aplikace a dávkování škodlivé účinky MeSH
- pozorné vyčkávání * statistika a číselné údaje MeSH
- progrese nemoci MeSH
- protinádorové látky * aplikace a dávkování škodlivé účinky MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
BACKGROUND: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved. METHODS: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring. Treatment was continued for 39 cycles, for 36 months, or until confirmation of disease progression, whichever occurred first. The primary end point was progression-free survival; progression to active multiple myeloma was assessed by an independent review committee in accordance with International Myeloma Working Group diagnostic criteria. RESULTS: Among the 390 enrolled patients, 194 were assigned to the daratumumab group and 196 to the active-monitoring group. With a median follow-up of 65.2 months, the risk of disease progression or death was 51% lower with daratumumab than with active monitoring (hazard ratio, 0.49; 95% confidence interval [CI], 0.36 to 0.67; P<0.001). Progression-free survival at 5 years was 63.1% with daratumumab and 40.8% with active monitoring. A total of 15 patients (7.7%) in the daratumumab group and 26 patients (13.3%) in the active-monitoring group died (hazard ratio, 0.52; 95% CI, 0.27 to 0.98). Overall survival at 5 years was 93.0% with daratumumab and 86.9% with active monitoring. The most common grade 3 or 4 adverse event was hypertension, which occurred in 5.7% and 4.6% of the patients in the daratumumab group and the active-monitoring group, respectively. Adverse events led to treatment discontinuation in 5.7% of the patients in the daratumumab group, and no new safety concerns were identified. CONCLUSIONS: Among patients with high-risk smoldering multiple myeloma, subcutaneous daratumumab monotherapy was associated with a significantly lower risk of progression to active multiple myeloma or death and with higher overall survival than active monitoring. No unexpected safety concerns were identified. (Funded by Janssen Research and Development; AQUILA ClinicalTrials.gov number, NCT03301220.).
Albert Schweitzer Hospital Dordrecht the Netherlands
Alexandra General Hospital National and Kapodistrian University of Athens Athens
Ankara University Ankara Turkey
Charles University and General Hospital Prague Czech Republic
Clínica Medica São Germano São Paulo
Cross Cancer Institute University of Alberta Edmonton Canada
GMMG Study Group at University Hospital Heidelberg Internal Medicine 5 Heidelberg Germany
Institut Català d'Oncologia and Institut Josep Carreras Hospital Germans Trias i Pujol Barcelona
Institute of Hematology and Transfusion Medicine Warsaw Poland
Janssen Research and Development Beerse Belgium
Janssen Research and Development Raritan NJ
Janssen Research and Development Shanghai China
Janssen Research and Development Spring House PA
Janssen Scientific Affairs Horsham PA
Japanese Red Cross Medical Center Tokyo
Jessa Hospital Hasselt Belgium
Kent and Canterbury Hospital Canterbury United Kingdom
Knight Cancer Institute Oregon Health and Science University Portland
Levine Cancer Institute Atrium Health Wake Forest University School of Medicine Charlotte NC
Medical Unit Hematology Karolinska University Hospital Stockholm
Ogaki Municipal Hospital Ogaki City Japan
Oslo Myeloma Center Department of Hematology Oslo University Hospital Oslo
Perth Blood Institute Murdoch University Perth WA Australia
Rigshospitalet University of Copenhagen Copenhagen
Tel Aviv Sourasky Medical Center and Tel Aviv University Tel Aviv Israel
University Hospital Hôtel Dieu Nantes France
University Hospital of Salamanca IBSAL and Cancer Research Center IBMCC Salamanca Spain
University of Washington and Fred Hutchinson Cancer Center Seattle
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015778
- 003
- CZ-PrNML
- 005
- 20250731091225.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1056/NEJMoa2409029 $2 doi
- 035 __
- $a (PubMed)39652675
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dimopoulos, Meletios A $u Alexandra General Hospital, National and Kapodistrian University of Athens, Athens
- 245 10
- $a Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma / $c MA. Dimopoulos, PM. Voorhees, F. Schjesvold, YC. Cohen, V. Hungria, I. Sandhu, J. Lindsay, RI. Baker, K. Suzuki, H. Kosugi, MD. Levin, M. Beksac, K. Stockerl-Goldstein, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, AK. Mylin, S. Bringhen, K. Uttervall, B. Pula, E. Medvedova, AJ. Cowan, P. Moreau, MV. Mateos, H. Goldschmidt, T. Ahmadi, L. Sha, A. Cortoos, EG. Katz, E. Rousseau, L. Li, RM. Dennis, R. Carson, SV. Rajkumar, AQUILA Investigators
- 520 9_
- $a BACKGROUND: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved. METHODS: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring. Treatment was continued for 39 cycles, for 36 months, or until confirmation of disease progression, whichever occurred first. The primary end point was progression-free survival; progression to active multiple myeloma was assessed by an independent review committee in accordance with International Myeloma Working Group diagnostic criteria. RESULTS: Among the 390 enrolled patients, 194 were assigned to the daratumumab group and 196 to the active-monitoring group. With a median follow-up of 65.2 months, the risk of disease progression or death was 51% lower with daratumumab than with active monitoring (hazard ratio, 0.49; 95% confidence interval [CI], 0.36 to 0.67; P<0.001). Progression-free survival at 5 years was 63.1% with daratumumab and 40.8% with active monitoring. A total of 15 patients (7.7%) in the daratumumab group and 26 patients (13.3%) in the active-monitoring group died (hazard ratio, 0.52; 95% CI, 0.27 to 0.98). Overall survival at 5 years was 93.0% with daratumumab and 86.9% with active monitoring. The most common grade 3 or 4 adverse event was hypertension, which occurred in 5.7% and 4.6% of the patients in the daratumumab group and the active-monitoring group, respectively. Adverse events led to treatment discontinuation in 5.7% of the patients in the daratumumab group, and no new safety concerns were identified. CONCLUSIONS: Among patients with high-risk smoldering multiple myeloma, subcutaneous daratumumab monotherapy was associated with a significantly lower risk of progression to active multiple myeloma or death and with higher overall survival than active monitoring. No unexpected safety concerns were identified. (Funded by Janssen Research and Development; AQUILA ClinicalTrials.gov number, NCT03301220.).
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D000911
- 650 12
- $a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $7 D000970
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 12
- $a mnohočetný myelom $x diagnóza $x epidemiologie $x prevence a kontrola $7 D009101
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 12
- $a doutnající mnohočetný myelom $x diagnóza $x mortalita $x terapie $7 D000075122
- 650 12
- $a pozorné vyčkávání $x statistika a číselné údaje $7 D057832
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Voorhees, Peter M $u Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
- 700 1_
- $a Schjesvold, Fredrik $u Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo
- 700 1_
- $a Cohen, Yael C $u Tel-Aviv Sourasky (Ichilov) Medical Center and Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Hungria, Vania $u Clínica Medica São Germano, São Paulo
- 700 1_
- $a Sandhu, Irwindeep $u Cross Cancer Institute, University of Alberta, Edmonton, Canada
- 700 1_
- $a Lindsay, Jindriska $u Kent and Canterbury Hospital, Canterbury, United Kingdom
- 700 1_
- $a Baker, Ross I $u Perth Blood Institute, Murdoch University, Perth, WA, Australia
- 700 1_
- $a Suzuki, Kenshi $u Japanese Red Cross Medical Center, Tokyo
- 700 1_
- $a Kosugi, Hiroshi $u Ogaki Municipal Hospital, Ogaki City, Japan
- 700 1_
- $a Levin, Mark-David $u Albert Schweitzer Hospital, Dordrecht, the Netherlands
- 700 1_
- $a Beksac, Meral $u Ankara University, Ankara, Turkey
- 700 1_
- $a Stockerl-Goldstein, Keith $u Washington University School of Medicine, St. Louis
- 700 1_
- $a Oriol, Albert $u Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona
- 700 1_
- $a Mikala, Gabor $u South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary
- 700 1_
- $a Garate, Gonzalo $u Hospital Alemán, Buenos Aires
- 700 1_
- $a Theunissen, Koen $u Jessa Hospital, Hasselt, Belgium
- 700 1_
- $a Spicka, Ivan $u Charles University and General Hospital, Prague, Czech Republic
- 700 1_
- $a Mylin, Anne K $u Rigshospitalet, University of Copenhagen, Copenhagen
- 700 1_
- $a Bringhen, Sara $u SSD Clinical Trials in Oncol-ematologia e Mieloma Multiplo, AOU Città della Salute e della Scienza di Torino, Turin, Italy
- 700 1_
- $a Uttervall, Katarina $u Medical Unit Hematology, Karolinska University Hospital, Stockholm
- 700 1_
- $a Pula, Bartosz $u Institute of Hematology and Transfusion Medicine, Warsaw, Poland
- 700 1_
- $a Medvedova, Eva $u Knight Cancer Institute, Oregon Health and Science University, Portland
- 700 1_
- $a Cowan, Andrew J $u University of Washington and Fred Hutchinson Cancer Center, Seattle
- 700 1_
- $a Moreau, Philippe $u University Hospital Hôtel-Dieu, Nantes, France
- 700 1_
- $a Mateos, Maria-Victoria $u University Hospital of Salamanca, IBSAL, and Cancer Research Center, IBMCC, Salamanca, Spain
- 700 1_
- $a Goldschmidt, Hartmut $u GMMG Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany
- 700 1_
- $a Ahmadi, Tahamtan $u Genmab US, Plainsboro, NJ
- 700 1_
- $a Sha, Linlin $u Janssen Research and Development, Shanghai, China
- 700 1_
- $a Cortoos, Annelore $u Janssen Scientific Affairs, Horsham, PA
- 700 1_
- $a Katz, Eva G $u Janssen Research and Development, Raritan, NJ
- 700 1_
- $a Rousseau, Els $u Janssen Research and Development, Beerse, Belgium
- 700 1_
- $a Li, Liang $u Janssen Research and Development, Shanghai, China
- 700 1_
- $a Dennis, Robyn M $u Janssen Research and Development, Raritan, NJ
- 700 1_
- $a Carson, Robin $u Janssen Research and Development, Spring House, PA
- 700 1_
- $a Rajkumar, S Vincent $u Mayo Clinic, Rochester, MN
- 710 2_
- $a AQUILA Investigators
- 773 0_
- $w MED00003517 $t The New England journal of medicine $x 1533-4406 $g Roč. 392, č. 18 (2025), s. 1777-1788
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39652675 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091220 $b ABA008
- 999 __
- $a ok $b bmc $g 2366547 $s 1252903
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 392 $c 18 $d 1777-1788 $e 20241209 $i 1533-4406 $m The New England journal of medicine $n N Engl J Med $x MED00003517
- LZP __
- $a Pubmed-20250708
